Receive The Newest Study Notifications

Successful trials demonstrating Rapid Acoustic Pulse (RAP) technology to reduce keloid and hypertrophic scars may be indicative of a wider range of fibrosis-related indication HOUSTON, Sept. 10, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"),...

For clinical trial recruitment companies to improve their numbers, they must take advantage of all forms of digital media. In the same vein, fishbat explains how social media can help increase patient recruitment and retention rates. To ensure utmost effectiveness for...

 Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the positive recommendation of the fourth and...

A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease. Preclinical research found that the drug -- called BPN14770 --...

Mark Terry for Biospace writes: Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. Novartis reported results from two clinical trials evaluating improvements in heart structure and function, as well as...

- Study will evaluate the potential of DSP107 and atezolizumab in NSCLC patients who are refractory to PD1/PD-L1 inhibitors - Patient enrolment expected to commence in H1/2020  KAHR Medical, a biopharmaceutical company developing a novel drug platform based on...

Evidence of Biological Activity in the Lung with Minimal Systemic Exposure Generally Well-Tolerated as a Single Dose in Healthy Volunteers and as a Once-daily Dose for Seven Days in Asthmatics DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH)...

Applied Molecular Transport (AMT), a clinical- stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 1b portion of a first-in-human clinical trial designed to evaluate the safety and tolerability of AMT-101, a novel oral...

Histogen, Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced its plans for clinical development of three key product candidates during the Company's presentation at the HC...

Sept. 9, 2019 13:00 UTC Successful completion of Fractyl’s first sham-controlled, multicenter clinical trial of Revita DMR to support EU commercial launch and inform U.S. pivotal clinical trial Revita-2 data support Revita DMR as a non-pharmacological intervention...

MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure...

Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the...

CytoDyn Inc. (OTC.QB:CYDY), ("CytoDyn" or the "Company"), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has allowed a Phase 2 study to proceed...

Sept. 8, 2019 12:00 UTC 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint)...

TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of death SM-88 is an oral, investigational cancer metabolism-based therapy that has...

Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not...

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of CYC065, a CDK2/9...

Clinical-stage pharma company Ocuphire Pharma, Inc has recently announced the completion of the first phase of their Two-Phase 2b Nyxol Eye Drops clinical studies, with the successful enrollment of 39 patients of glaucoma in the ORION-1 at 5 sites across the US from...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which aims to further modernize drug development,...

Usona Institute launches its Phase 2 study of psilocybin for major depressive disorder this fall. The study, PSIL201, will be conducted at seven U.S. sites and will investigate the safety and efficacy of psilocybin for major depressive disorder (MDD). The open dates...